Posted: 1 August 2024 Patrys Limited. a therapeutic antibody development company, provides the following update regarding the recently completed GMP manufacturing run of PAT-DX1. Patrys’ Contract Development Manufacturing Organization (CDMO) advised the Company that it has identified an…
Posted: 1 August 2024 The Department of Health and Aged Care is conducting a national audit of the Health and Medical Research Workforce, with the findings helping to inform the development of the National Health and Medical Research…
Posted: 31 July 2024 Babies with peanut allergies in Australia will be offered a treatment program under a world-first model aiming to transform allergy care. Ten paediatric hospitals across five states have partnered with the National Allergy Centre of…
Posted: 31 July 2024 The Commonwealth Government’s Medical Research Future Fund (MRFF) has invested $4 million into establishing Australia’s first National Centre for Biopharmaceutical Optimisation of mRNA Therapeutics (CORTx), being led by Monash University to optimise mRNA therapeutic…
Posted: 31 July 2024 The Albanese Government is awarding more than $19 million to six research projects that use mRNA – the medical technology that underpins the Pfizer and Moderna COVID vaccines – to find vaccines to prevent…
Posted: 31 July 2024 Using cutting-edge CRISPR technology, researchers have successfully managed to reduce hepatitis B virus levels in the laboratory, lowering key viral markers by up to 96 per cent. This advancement paves the way for a…
Posted: 31 July 2024 A key receptor is being targeted using robotic high-throughput screening at the National Drug Discovery Centre (NDDC) to fast-track new treatments for endometriosis. Advancing endometriosis treatment research Endometriosis affects 10% of women of reproductive…
Posted: 30 July 2024 Telix is pleased to announce that it has successfully priced A$650 million 2.375 per cent convertible notes due 2029. The convertible notes, also referred to as “convertible bonds” (Convertible Bonds), are convertible into fully…
Posted: 29 July 2024 Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has entered into a Technology Licence Agreement (TLA) with The…
Posted: 29 July 2024 Telix today announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the filing of its New Drug Application (NDA) for TLX007-CDx, a new and proprietary cold kit (“Kit”) for the…
Posted: 23 July 2024 Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced positive interim data from the ATH434-202 open-label Phase 2 clinical…
Posted: 23 July 2024 Burnet Senior Research Officer Dr Liriye Kurtovic has been awarded a Moderna Global Fellowship to support her research into the development of a new malaria vaccine. The coveted fellowship supports scientists and healthcare professionals…